Zidovudin etkileşimleri

antiretroviral sınıfından Zidovudin (Retrovir) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 70 belgelenmiş etkileşim var: 37 majör, 26 orta, 5 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 2 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (37)

  • AbakavirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Abakavir ve lamivudinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • AdefovirantiviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [See Warnings and Precautions (5. (Adefovir etiketi, Kutulu uyarı)

  • AtazanavirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • DarunavirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Darunavir ve kobisistatantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • • Avoid use with doxorubicin. (Zidovudin etiketi, İlaç etkileşimleri)

  • DolutegravirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • DoravirinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • EfavirenzantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • EmtrisitabinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Emtrisitabin ve tenofovirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • EntekavirantiviralMajör

    Therapy with BARACLUDE is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) [see Warnings and Precautions (5.2) ] . (Entekavir etiketi, Kutulu uyarı)

  • EtravirinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • FosamprenavirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • HidroksiüreantimetabolitMajör

    Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis Pancreatitis (including fatal cases) have occurred in patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine. (Hidroksiüre etiketi, İlaç etkileşimleri)

  • KabotegravirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • KladribinantimetabolitMajör

    Antiviral and antiretroviral drugs: Avoid concomitant use. (Kladribin etiketi, İlaç etkileşimleri)

  • LamivudinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Lamivudin ve zidovudinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. (Ledipasvir ve sofosbuvir etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Lopinavir ve ritonavirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • MaravirokantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • NevirapinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • RaltegravirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • RibavirinantiviralMajör

    Coadministration of ribavirin and zidovudine is not advised. (Zidovudin etiketi, Uyarılar ve önlemler)

  • RifabutinantibiyotikMajör

    Therefore, co-administration with antiretroviral and anti-HCV drugs metabolized by CYP3A is not recommended or there may be a need to increase the dose of antiretroviral or anti-HCV drugs (see PRECAUTIONS-Drug Interactions ). (Rifabutin etiketi, Uyarılar)

  • RifampisinantibiyotikMajör

    …Concentrations Administered with rifampin 600 mg daily, unless otherwise specified AUC = area under the time-concentration curve Drug or Drug Class and Prevention or Management Clinical Effect Antiretrovirals Prevention or Management: Concomitant use is contraindicated (see CONTRAINDICATIONS ) Atazanavir Decrease AUC by 72% Darunavir Rifampin dosage used concomitantly with… (Rifampisin etiketi, İlaç etkileşimleri)

  • RilpivirinantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • RitonavirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

  • Sarı kantaronBitkisel ürün ve takviyeMajör

    Sarı kantaron, bazı HIV ilaçlarının kan düzeylerini tedavinin başarısız olmasına yol açacak kadar düşürebilir. (NCCIH, St. John's Wort)

  • TenofovirantiretroviralMajör

    Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. (Zidovudin etiketi, Kutulu uyarı)

Orta düzey etkileşimler (26)

  • Antiretrovirals: Patients who are on chronic buprenorphine treatment should have their dose monitored if NNRTIs are added to their treatment regimen. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

  • Dekslansoprazolproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance . (Dekslansoprazol etiketi, İlaç etkileşimleri)

  • Divalproeks (valproat)antikonvülsanOrta

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (Divalproeks (valproat) etiketi, İlaç etkileşimleri)

  • EluksadolinopioidOrta

    Examples: cyclosporine, gemfibrozil, antiretrovirals (atazanavir, lopinavir, ritonavir, saquinavir, tipranavir), rifampin, eltrombopag Drugs that Cause Constipation Clinical Impact: Increased risk for constipation related adverse reactions and potential for constipation related serious adverse reactions Intervention: Avoid use with other drugs that may cause… (Eluksadolin etiketi, İlaç etkileşimleri)

  • Esomeprazolproton pompası inhibitörüOrta

    • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with esomeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ] . (Esomeprazol etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalOrta

    (See CLINICAL PHARMACOLOGY: Drug Interaction Studies . ) Zidovudine Fluconazole increases the C max and AUC of zidovudine by 84% and 74%, respectively, due to an approximately 45% decrease in oral zidovudine clearance. (Flukonazol etiketi, İlaç etkileşimleri)

  • GansiklovirantiviralOrta

    Hematologic/Bone Marrow Suppressive/Cytotoxic Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine. (Zidovudin etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikOrta

    Zidovudine Zidovudine: Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. (Klaritromisin etiketi, İlaç etkileşimleri)

  • Lansoprazolproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance. (Lansoprazol etiketi, İlaç etkileşimleri)

  • LeflunomidimmünosüpresanOrta

    In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (Leflunomid etiketi, İlaç etkileşimleri)

  • MetadonopioidOrta

    Zidovudine Experimental evidence demonstrated that methadone increased the AUC of zidovudine which could result in toxic effects. (Metadon etiketi, İlaç etkileşimleri)

  • • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with esomeprazole magnesium may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology (12.3) ]. (Naproksen ve esomeprazol etiketi, İlaç etkileşimleri)

  • Omeprazolproton pompası inhibitörüOrta

    • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )]. (Omeprazol etiketi, İlaç etkileşimleri)

  • Omeprazol ve sodyum bikarbonatproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance [see Clinical Pharmacology ( 12.3 )] . (Omeprazol ve sodyum bikarbonat etiketi, İlaç etkileşimleri)

  • Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (Orlistat etiketi, Uyarılar ve önlemler)

  • Pantoprazolproton pompası inhibitörüOrta

    • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with pantoprazole may reduce antiviral effect and promote the development of drug resistance. (Pantoprazol etiketi, İlaç etkileşimleri)

  • PirimetaminantimalaryalOrta

    However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim- sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. (Pirimetamin etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalOrta

    Anti-HIV Drugs that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Ritonavir and atazanavir are CYP3A4 substrates and posaconazole increased plasma concentrations of these drugs [see Clinical Pharmacology (12.3) ]. (Posakonazol etiketi, İlaç etkileşimleri)

  • Rabeprazolproton pompası inhibitörüOrta

    Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance. (Rabeprazol etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikOrta

    Fixed-Dose Combination of Efavirenz, Emtricitabine, and Tenofovir Once-weekly coadministration of 900 mg PRIFTIN with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine,… (Rifapentin etiketi, İlaç etkileşimleri)

  • SidofovirantiviralOrta

    Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of cidofovir infusion. (Sidofovir etiketi, İlaç etkileşimleri)

  • SiklofosfamidimmünosüpresanOrta

    …can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone ● G-CSF,… (Siklofosfamid etiketi, İlaç etkileşimleri)

  • TerbinafinantifungalOrta

    The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant. (Terbinafin etiketi, İlaç etkileşimleri)

  • TeriflunomidimmünosüpresanOrta

    In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (Teriflunomid etiketi, İlaç etkileşimleri)

  • ValgansiklovirantiviralOrta

    …myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine) Unknown Because of potential for higher toxicity, coadministration with valganciclovir hydrochloride should be considered only if the potential benefits are judged to outweigh… (Valgansiklovir etiketi, İlaç etkileşimleri)

  • Valproik asitantikonvülsanOrta

    Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with valproic acid oral solution (7.2) (Valproik asit etiketi, İlaç etkileşimleri)

Minör değinmeler (5)

  • BuprenorfinopioidMinör

    Intervention: None Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Clinical Impact: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. (Buprenorfin etiketi, İlaç etkileşimleri)

  • HidrokortizonkortikosteroidMinör

    Examples: Anti-fungals: itraconazole, posaconazole, voriconazole Antibiotics: erythromycin and clarithromycin Antiretrovirals: ritonavir Grapefruit juice CYP3A4 Inducers Clinical Impact: Hydrocortisone is metabolized by cytochrome P450 3A4 (CYP3A4). (Hidrokortizon etiketi, İlaç etkileşimleri)

  • Anti-HIV efavirenz, maraviroc, nevirapine, zidovudine, bictegravir/ emtricitabine/ tenofovir ↑ efavirenz ↑ maraviroc ↑ nevirapine ↓ zidovudine ↑ bictegravir ↔ emtricitabine ↑ tenofovir For further information, refer to the respective anti-HIV drugs prescribing information. (Nirmatrelvir ve ritonavir etiketi, İlaç etkileşimleri)

  • PentamidinQT aralığını uzatan ilaçMinör

    Drug Interactions While specific studies on drug interactions with Pentamidine Isethionate have not been conducted, the majority of patients in clinical trials received concomitant medications, including zidovudine, with no reported interactions. (Pentamidin etiketi, İlaç etkileşimleri)

  • Antiretrovirals: atazanavir lopinavir ↑ voxilaprevir Coadministration of VOSEVI with atazanavir- or lopinavir-containing regimens is not recommended. tipranavir/ritonavir ↓ sofosbuvir ↓ velpatasvir Coadministration is not recommended. (Sofosbuvir ve velpatasvir etiketi, İlaç etkileşimleri)

Anlamlı etkileşim olmadığı bildirilenler (2)

  • FamsiklovirantiviralEtkileşim yok

    No clinically significant effect on the pharmacokinetics of zidovudine, its metabolite zidovudine glucuronide, or emtricitabine was observed following a single oral dose of 500 mg famciclovir coadministered with zidovudine or emtricitabine. (Famsiklovir etiketi, İlaç etkileşimleri)

  • MegestrolprogestinEtkileşim yok

    Zidovudine and Rifabutin No dosage adjustment for zidovudine and rifabutin is needed when megestrol acetate is coadministered with these drugs [See Clinical Pharmacology ( 12.3 )] . (Megestrol etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Zidovudin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.